Expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.
Addressing threats of harm to children by modifying the child removal standard related to another person's use or possession of a high-potency synthetic opioid.